OncoMatch/Leukemia — Chronic Myeloid (CML)/BCR::ABL1
Leukemia — Chronic Myeloid (CML)BCR::ABL1 Clinical Trials
BCR::ABL1 fusion is the defining oncogene of CML, present in virtually all cases, and drives constitutive tyrosine kinase signaling amenable to targeted TKI therapy. Imatinib, dasatinib, nilotinib, bosutinib, and ponatinib are approved across lines of therapy; deep molecular response (MR4.5) enables treatment-free remission (TFR) attempts. Trials investigate asciminib (a STAMP inhibitor active against T315I), TFR optimization strategies, and approaches to blast phase CML.
Top recruiting BCR::ABL1 Leukemia — Chronic Myeloid (CML) trials
Ranked by phase and US site count. See all 23 trials matched to your profile →
A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs
Il-Yang Pharm. Co., Ltd.
Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System
Poitiers University Hospital
A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)
Terns, Inc.
Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase
Augusta University
KRT-232 and TKI Study in Chronic Myeloid Leukemia
Kartos Therapeutics, Inc.
Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population
Baylor College of Medicine
Browse other molecular targets with active Leukemia — Chronic Myeloid (CML) trials.